๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-05-02

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) (NCT07298915)

๐ŸŸก Not Yet Recruiting Phase3 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: University of Virginia

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life Participants will: * Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (19 items).

Location: University of Virginia โ€” Charlottesville, Virginia

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Including but not limited to serious arrhythmias
  • Cardiomyopathy
  • Congestive heart failure
  • Stroke or transient ischemic attacks
  • Peripheral vascular disease
  • Previous history of myocardial infarction or stroke
  • Previous diagnosis or taking medication for type 1 or 2 diabetes, fasting glucose \>125 mg/dL or HbA1C โ‰ฅ6.5%
  • Systolic blood pressure \>160 mmHg and diastolic blood pressure \>100 mmHg.
  • Hospitalization for mental illness within the past 5 years or currently undergoing treatment for severe mental illness
  • Conditions that can be aggravated or are contraindicated by exercise training
  • Plans to be out of town more than 3 weeks in the next 4 months.

๐Ÿ” Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • University of Virginia โ€” Charlottesville, Virginia

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
๐Ÿ›๏ธ View Official NIH Record โ†—